<DOC>
	<DOCNO>NCT00992160</DOCNO>
	<brief_summary>This study 28-day polysomnographic subjective assessment oral Vestipitant 15mg/day treatment Primary Insomnia adult outpatient .</brief_summary>
	<brief_title>Vestipitant 28-day Tolerance Study</brief_title>
	<detailed_description />
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Vestipitant</mesh_term>
	<criteria>Male female age 1864 year inclusively Diagnosis Primary Insomnia accord Diagnostic Statistical Manual Mental Disorders Text Revision ( DSMIVTR ) criteria 307.42 PSG variable collect 2consecutive PSG screen night fall follow : TST 240420 min inclusive ( night ) LPS ( Latency Persistent Sleep ) : mean le 20mins , night le 15 min WASO ( Wake After Sleep Onset ) : mean le 60mins , night le 45mins Women : non child bear potential child bear potential agree Contraceptive Methods list Protocol clinically significant Psychiatric neurological disorder ( sleep disorder Primary Insomnia , history alcohol orother substance abuse dependnce ) ; nightshift rotate shiftwork ; Lifestyle habit agreement Protocol requirement : caffeine alcohol intake smoke healthy accord GSK criterion laboratory ECG limit set Protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Polysomnography ( PSG )</keyword>
	<keyword>Adults</keyword>
	<keyword>Primary Insomnia</keyword>
</DOC>